JDRF Applauds the Government of Manitoba for Launching the Pediatric Insulin Pump Program
TORONTO (April 12, 2012) – JDRF applauds the Government of Manitoba for launching the Pediatric Insulin Pump Program.
Insulin pump technology provides precise insulin delivery continuously day and night, helping individuals maintain glucose levels between meals, during exercise and overnight. Studies have shown that people living with type 1 diabetes who use insulin pump therapy experience fewer complications and live longer, healthier lives. The Pediatric Insulin Pump Program will help children and families manage their diabetes.
“JDRF welcomes this announcement and commends the Government of Manitoba for taking the necessary steps to help ease the burden of diabetes on families in Manitoba,” said Andrew McKee, President and CEO, JDRF. “We thank the Government for its efforts as there has never been a greater need to cure, better treat and prevent diabetes.”
Affecting over 300,000 Canadians, type 1 diabetes can occur at any age, leaving children and adults dependent on injected or pumped insulin for life. The number of people living with type 1 diabetes is increasing by three to five per cent annually - the greatest rise being in children aged five to nine years.
“Diabetes continues to have an impact on millions of Canadians and their families,” says McKee. “Through initiatives such as these, we are making real progress in improving the lives of those living with type 1 diabetes. We look forward to working with the Government of Manitoba as we progress toward our goal of curing type 1 diabetes.”
JDRF is the leading global organization focused on type 1 diabetes (T1D) research. Driven by passionate, grassroots volunteers connected to children, adolescents, and adults with this disease, JDRF is now the largest charitable supporter of T1D research. The goal of JDRF research is to improve the lives of every person affected by T1D by accelerating progress on the most promising opportunities for curing, better treating, and preventing T1D. JDRF collaborates with a wide spectrum of partners who share this goal.
Since its founding in 1970, JDRF has awarded more than $1.6 billion to diabetes research. Past JDRF efforts have helped to significantly advance the care of people with this disease, and have expanded the critical scientific understanding of T1D. JDRF will not rest until T1D is fully conquered.
For more information, please visit www.jdrf.ca.
For More Information:
Associate Vice President, Marketing and Communications